Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 78.8%

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 107,470 shares, a decline of 78.8% from the July 15th total of 506,729 shares. Currently, 3.6% of the company’s stock are short sold. Based on an average trading volume of 138,757 shares, the short-interest ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Exicure Stock Performance

NASDAQ:XCUR traded up $0.01 during midday trading on Thursday, reaching $1.31. 50,639 shares of the stock traded hands, compared to its average volume of 103,315. The stock has a market capitalization of $8.34 million, a PE ratio of -0.85 and a beta of 3.65. Exicure has a 12-month low of $1.18 and a 12-month high of $9.48. The business has a 50-day moving average of $1.99 and a two-hundred day moving average of $3.16.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($18.60) by $18.31.

About Exicure

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.